Eliem Therapeutics, Inc Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ELYM Company Description
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
ELYM Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ELYM Smart Score
Score Breakdown
ELYM Company Description
Show More
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS). Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ELYM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ELYM's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of ELYM in WallStreetBets Daily Discussion
ELYM News
Recent insights relating to ELYM
CNBC Recommendations
Recent picks made for ELYM stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ELYM
Corporate Flights
Flights by private jets registered to ELYM
Our Analysis